Abstract:Purpose: The purpose of this study was to assess the efficacy of an iodine-125 (125I) seed strand combined with a metal stent compared with a metal stent for treatment of obstructive jaundice caused by pancreatic ductal adenocarcinoma (PDAC). Methods and materials: A retrospective analysis was carried out of patients who were referred to Shanghai Zhongshan Hospital of Fudan University with a diagnosis of PDAC between January 1, 2010 and January 31, 2019. A total of 110 consecutive patients with obstructive jaundice caused by PDAC were divided into the iodine-125 seed strand combined with a metal stent group (Group A = 48) and the metal stent group (Group B = 62). The primary outcome was stent obstruction-free survival time, and secondary outcomes were overall survival and complications. Results: The median stent obstruction-free survival time was 133.0 (95% confidence interval (CI): 166.093-149.907) days, and the median overall survival was 212.0 (95% CI: 187.183-236.817) days in all patients. Median stent obstruction-free survival time was 175 days (95% CI 103.165-246.835 days) in Group A versus 120 days (95% CI 87.475-152.525 days) in Group B (p = 0.035). A lower Eastern Cooperative Oncology Group (ECOG) score (p = 0. 000) and iodine-125 seed strand combined with metal stent implantation (p = 0.008) were associated with a longer stent obstruction-free survival time. Obstruction length (p = 0.083), ECOG score (p = 0.000), and iodine-125 seeds (p = 0.037) might have potential impact on stent obstruction-free survival time and were included for multivariable analysis using the Cox proportional hazards model. Stent restenosis was observed in 18.8% (9/48) of patients in Group A and 54.8% (34/62) in Group B, respectively. There was no significant difference in median survival between Group A and Group B (p = 0.409). The median survival in Group A was 209 days (95% CI 150.750-267.250) and 202 days (95% CI 190.624-233.376) in Group B. The median survival of patients with a lower ECOG score was better than that of patients with a higher ECOG score (267 days vs 132 days, p = 0.000). The Grade 3 or 4 complications occurred in 4 (8.3%) of the 48 patients in Group A (one case of hemobilia, one case of liver abscess, two cases of choleperitonitis) and in 5 (8.1%) of the 62 patients in Group B (one case of hemobilia, two cases of liver abscess, two cases of choleperitonitis) (p = 0.972). Conclusions: Implantation of an iodine-125 seed strand combined with a metal stent provides longer obstruction-free survival time compared with a metal stent in patients with obstructive jaundice caused by PDAC. It seems reasonable to choose an iodine-125 seed strand combined with a metal stent as a treatment for these patients.

Malignant Obstructive Jaundice Treated with Intraluminal Placement of Iodine-125 Seed Strands and Metal Stents: an Analysis of Long-Term Outcomes and Prognostic Features

Malignant Obstructive Jaundice Treated by Intraluminal Brachytherapy Combined with Stent Placement or Stent Implantation Alone

The Use of 125I Seed Strands for Intraluminal Brachytherapy of Malignant Obstructive Jaundice

Comparison of Intraluminal Brachytherapy Combined with and Without Stent Placement for Treatment of Obstructive Jaundice Induced by Tumor Thrombus.

HDR-^192Ir Intraluminal Brachytherapy in Treatment of Malignant Obstructive Jaundice

Biliary stent combined with iodine-125 seed strand implantation in malignant obstructive jaundice

Biliary Stent With Or Without I-125 Seeds For Malignant Obstructive Jaundice: A Systematic Review And Meta-Analysis

Iodine-125 Seeds Combined with Biliary Stent Placement Versus Stent Placement Alone for Unresectable Malignant Biliary Obstruction: A Meta-Analysis of Randomized Controlled Trials

Biliary stent with or without 125 I seeds for malignant obstructive jaundice : a systematic review and meta-analysis

Efficacy and Safety of the Treatment of 125I Seeds Combined with Stent Implantation for Patients with Malignant Obstructive Jaundice: A Meta-Analysis

Effects Of Radioactive Iodine-125 Seed Implantation On Therapeutic Efficacy, Serum Vegf, Cea Levels, And Prognosis Of Patients With Ocular Malignant Tumors

Percutaneous Drainage and Stenting for Treatment of Malignant Obstruction of Bile Duct

Malignant obstructive jaundice - brachytherapy as a tool for palliation

A Pilot Study of Intraluminal Brachytherapy Using 125I Seed Strand for Locally Advanced Pancreatic Ductal Adenocarcinoma with Obstructive Jaundice.

An iodine-125 seed strand combined with a metal stent versus a metal stent alone for obstructive jaundice caused by pancreatic ductal adenocarcinoma

Preliminary application of brachytherapy with double-strand 125I seeds and biliary drainage for malignant obstructive jaundice

Self-expandable metallic stent with 125I seed strand in malignant biliary obstruction: a self-made delivery system and novel implantation method

Clinical outcomes of intraluminal Iodine-125 seed strand brachytherapy and percutaneous nephrostomy in patients with ureteral carcinoma

Damage to Pig Bile Duct Caused by Intraluminal Brachytherapy Using a (125)I Ribbon.

Hepatic arterial infusion chemotherapy following simultaneous metallic stent placement and iodine-125 seed strands for advanced cholangiocarcinoma causing malignant obstructive jaundice: a propensity score matching study

Implanting Iodine-125 Seed Strand Inside the Portal Vein Stent: an Improved Approach to Endovascular Brachytherapy for Treatment of Patients with Hepatocellular Carcinoma and Main Portal Vein Tumor Thrombus